SCHEMBL9890735

SCHEMBL9890735

CNC(=O)Cc1ccccc1-c1cccc(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.44
CHRM3 P20309 1/20 0.44
PTGER1 P34995 2/20 0.41
PTGER4 P35408 2/20 0.41
PTGER3 P43115 2/20 0.41
PTGER2 P43116 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
GAA P10253 1/20 0.40
ENPP2 Q13822 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
SHMT1 P34896 2/20 0.38
SHMT2 P34897 2/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394292 0.84 FFAR1 (0.47) CHRM1CHRM3PTGER1PTGER4PTGER3
SCHEMBL2393550 0.84 SLC6A3 (0.48) ALDH1A1HTTGAAMAPTMEN1
SCHEMBL2397419 0.83 KMT2A (0.51) CHRM1CHRM3ALDH1A1KMT2AL3MBTL1
SCHEMBL2393439 0.83 SMN1; SMN2 (0.46) CHRM1CHRM3PTGER1PTGER4PTGER3
SCHEMBL9890716 0.83 CHRM1 (0.62) CHRM1CHRM3PTGER1PTGER4PTGER3
SCHEMBL9890646 0.82 PTGER1 (0.57) PTGER1PTGER4PTGER3PTGER2ALDH1A1
SCHEMBL2395342 0.81 PTGDR2 (0.43) ALDH1A1HTTMEN1KMT2AL3MBTL1
SCHEMBL2391274 0.81 PTGER1 (0.44) CHRM1CHRM3PTGER1PTGER4PTGER3
SCHEMBL9890750 0.81 MTNR1A (0.54) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL9890751 0.81 PTGER1 (0.52) CHRM1CHRM3PTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM3 298/4885PTGER1 1182/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM3 298/4885PTGER1 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.